Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Perspective Therapeutics (CATX) Payables (2016 - 2025)

Perspective Therapeutics' Payables history spans 15 years, with the latest figure at $13.2 million for Q3 2025.

  • For Q3 2025, Payables fell 39.61% year-over-year to $13.2 million; the TTM value through Sep 2025 reached $13.2 million, down 39.61%, while the annual FY2024 figure was $10.4 million, 49.4% up from the prior year.
  • Payables for Q3 2025 was $13.2 million at Perspective Therapeutics, up from $7.1 million in the prior quarter.
  • Across five years, Payables topped out at $21.9 million in Q3 2024 and bottomed at $98000.0 in Q2 2021.
  • The 5-year median for Payables is $3.9 million (2023), against an average of $5.1 million.
  • The largest YoY upside for Payables was 2104.44% in 2021 against a maximum downside of 85.02% in 2021.
  • A 5-year view of Payables shows it stood at $847000.0 in 2021, then skyrocketed by 81.94% to $1.5 million in 2022, then skyrocketed by 351.52% to $7.0 million in 2023, then skyrocketed by 49.4% to $10.4 million in 2024, then increased by 27.01% to $13.2 million in 2025.
  • Per Business Quant, the three most recent readings for CATX's Payables are $13.2 million (Q3 2025), $7.1 million (Q2 2025), and $8.8 million (Q1 2025).